From the JCI Editor: New Impact Factor and launch of Research Letters

Dear Colleague,

On behalf of the Journal of Clinical Investigation’s Editorial Board, I am humbled by the opportunity to serve the ASCI and to have the privilege of determining the cutting-edge biomedical research published by the Journal. I am delighted to share with you that the JCI’s latest Journal Impact Factor (IF) is 19.456, representing a 24% increase from the previous year. Our sister journal, JCI Insight, has also increased its IF, which now stands at 9.484. This strong performance highlights the strength of our authors’ articles and reflects the importance of our mission to understand the basis of human disease. We are grateful to our authors for entrusting us with their work, to our reviewers and consulting editors for their dedication to maintaining the highest standards, and to the prior editorial team at Johns Hopkins for their expert leadership during the unprecedented challenges of the pandemic. These successes affirm the ASCI’s voice and the critical role of societies in the publishing landscape.

As stewards of the JCI, the Northwestern-based Editorial Board is dedicated to continuing and improving the Journal’s record of excellence. We encourage submission of Research manuscripts that define disease processes. We welcome work that utilizes human data, from “n of one” to “big data” studies, while remaining interested in translationally relevant animal models and preclinical investigation. We also encourage Clinical Medicine submissions focused on human studies that have the potential to impact clinical practice or inform understanding of diseases.

Recognizing the need to disseminate certain high-impact findings quickly, we have launched a new submission category, Research Letters — focused reports of an original preclinical or clinical research finding of exceptional interest to the JCI readership presented in a single-figure (or -table) format.

As a reminder, ASCI dues-paying members who are the corresponding author of a first-round submission to the JCI, and whose dues are current, may designate one submission per calendar year to be guaranteed for external peer review. We encourage you to take advantage of this benefit by sending us your best work that advances the understanding of pathogenesis.

I wish you all the best and thank you for your support of the JCI.

Sincerely,

Elizabeth M. McNally, MD, PhD
Editor, The Journal of Clinical Investigation
Officer, ASCI Council